WashIn /WashOut Procedure To Prevent Agitation During Recovery After Inhalational Anesthesia With Sevoflurane
Launched by I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY · Feb 19, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method called the Wash In/Wash Out procedure to help prevent agitation in patients recovering from inhalational anesthesia, specifically with a gas called sevoflurane. Agitation can happen after surgery and may lead to longer recovery times and other complications, so finding ways to reduce it is important. The goal of this trial is to see if this new technique can lower the chances of experiencing agitation during recovery from surgery.
To be eligible for this trial, participants need to be at least 18 years old, scheduled for open abdominal surgery under general anesthesia, and able to provide written consent. Unfortunately, patients who are pregnant, have certain mental health conditions, or are taking specific medications will not be able to participate. Those who join the study can expect to be monitored closely during their recovery, and their experiences will help researchers understand if this new procedure can improve recovery outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Written informed consent from participants
- • 2. Age ≥ 18 years
- • 3. Planned open abdominal surgery
- • 4. General anesthesia
- Exclusion Criteria:
- • 1. Pregnant patients and breastfeeding patients
- • 2. Mental disorders
- • 3. Epilepsy, Parkinson disease, Alzheimer, peripheral nerve and neuromuscular junction pathology (amyotrophic lateral sclerosis, Guillain-Barre Syndrome, myasthenia gravis et cet.)
- • 4. Use of antidepressants, antipsychotics, sedatives, psychoactive drugs within a month before surgery.
About I.M. Sechenov First Moscow State Medical University
i.m. Sechenov First Moscow State Medical University is a prestigious institution dedicated to advancing medical education, research, and clinical practice. As a leading center for medical innovation in Russia, the university fosters a collaborative environment for scientific inquiry and the development of novel therapies. With a commitment to high-quality clinical trials, i.m. Sechenov aims to contribute significantly to the global biomedical landscape by evaluating new treatments and improving patient care through rigorous research methodologies and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Patients applied
Trial Officials
Valery Likhvantsev
Study Director
I.M. Sechenov First Moscow State Medical University (Sechenov University); Head of Research V. Negovsky Reanimatology Research Institute
Giovanni Landoni
Study Chair
San Raffaele Scientific Institute
Pavel Bagdasarov
Principal Investigator
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials